Expanded use of insulin glargine and lixisenatide injection

May 8, 2019 0 By FM

The US FDA has approved the expanded use of insulin glargine and lixisenatide injection (Soliqua 100/33) for patients uncontrolled on oral antidiabetic medicines.

The injection was previously approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide.

The FDA approval was based on data from the LixiLan-O clinical trial which showed, in adults with type 2 diabetes uncontrolled with metformin and/or a second oral antidiabetic therapy, that treatment with the injection led to significantly greater reductions in blood sugar levels.